2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMOCompleted
Determine speech understanding in noise with the AB*s bimodal BF directional hearing technology.